NCT04173832

Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study of Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 30 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double-blind, placebo-controlled, multi-center clinical trial was conducted to observe the improvement in the level of dyskinesia in patients with Parkinson's disease during the 12-week period of oral treatment with Tianqi Pingchan Granule Combined With Amantadine. To observe the differences of the safety and effectiveness between Tianqi Pingchan Granule combined with amantadine and placebo combined with amantadine.

Conditions

• L-DOPA-Induced Dyskinesia

Interventions

Type	Name	Description
DRUG	Tianqi Pingchan Granule Combined With Amantadine	Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
DRUG	Placebo Combined With Amantadine	Placebo and Amantadine are given to patients simultaneously

Timeline

• Start date: 2020-01-01
• Primary completion: 2020-12-31
• Completion: 2021-12-31
• First posted: 2019-11-22
• Last updated: 2020-12-01

Locations

1 site across 1 country: China